← Human Trials & Peer-Reviewed Studies
Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles
Plain-language guide to PMID 16926261 (2006): placebo-controlled randomized controlled trial study of Triptorelin.
Key Facts
- PMID
- 16926261
- Journal
- Human reproduction (Oxford, England)
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Tesarik J et al. (5 authors)
- DOI
- 10.1093/humrep/del173
- Registered trial
- NCT04174378
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Triptorelin.
This prospective randomized study evaluates the effect of GnRH agonist administered in the luteal phase on ICSI outcomes in both GnRH agonist- and GnRH antagonist-treated ovarian stimulation protocols.
Who Took Part
PubMed indexes the participants as adults, women only.
Six hundred women about to undergo ovarian stimulation for ICSI (300 using a long GnRH agonist protocol and 300 using a GnRH antagonist protocol) were enrolled in this study.
Patients treated with each of these two protocols were randomly assigned to receive a single injection of GnRH agonist or placebo 6 days after ICSI.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Triptorelin group a baseline to be compared against.
Implantation and live birth rates were the primary outcomes.
What Was Measured
This prospective randomized study evaluates the effect of GnRH agonist administered in the luteal phase on ICSI outcomes in both GnRH agonist- and GnRH antagonist-treated ovarian stimulation protocols.
The subject headings attached to it are Embryo Implantation, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Infertility, Female, Luteinizing Hormone, Ovulation Induction and Patient Selection.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Triptorelin.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (Human reproduction (Oxford, England)), a journal based in England.
More context: the Triptorelin compound page.
Our Notes on the Compound
Triptorelin: A 10-amino-acid GnRH analog (Trelstar, Decapeptyl, Triptodur) used in prostate cancer, early puberty and fertility protocols.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.